Creative Medical Technology Holdings Inc. (CELZ) Total Debt to Equity Ratio

Creative Medical Technology (CELZ) specializes in regenerative male health treatments utilizing AmnioStem cellular products. This price chart from GURU.Markets demonstrates a debt-to-equity ratio of 0.00. The company's monopoly pricing power is bolstered by the implementation of automated bioreactors to eliminate human error, as well as the ownership of unique patents in the field of immunomodulation.

Creative Medical Technology Holdings Inc. - CELZ Debt to Capital (period 07/04/2022 - 10/27/2026)

Analytical breakdowns and data insights for company Creative Medical Technology Holdings (CELZ)

- price and consensus price forecast:

Price Chart Creative Medical Technology Holdings, Inc.|CELZ - Analyst Median Target

- market capitalization data:

Market Valuation Creative Medical Technology|CELZ - Aggregate Business Value

- book capitalization data:

Book Value per Share Creative Medical Technology|CELZ - Total Stockholders' Equity|Market Value to Book Value Ratio creativemedicaltechnology.com|CELZ - Cumulative Company Assets

- debt and liquidity data:

Total Debt to Capital Creative Medical Technology|CELZ - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Creative Medical Technology Holdings, Inc.|CELZ - Company Cumulative Debt|Debt to Book Capitalization Ratio Creative Medical Technology

Summary company analysis:CELZ, Creative Medical Technology

To minimize capital loss risks amid volatility, investors must analyze the total debt-to-equity ratio, which measures the proportion of borrowed funds relative to the company's own resources to assess financial leverage. This metric determines the balance sheet resilience of Creative Medical Technology (CELZ) to rising Fed rates, which is critical for a venture business in the non-cyclical cell therapy sector.

Key competitors